%0 Journal Article
%T Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure
%A Minke H de Ru
%A Quirine GA Teunissen
%A Johanna H van der Lee
%A Michael Beck
%A Olaf A Bodamer
%A Lorne A Clarke
%A Carla E Hollak
%A Shuan-Pei Lin
%A Maria-Ver¨Žnica Rojas
%A Gregory M Pastores
%A Julian A Raiman
%A Maurizio Scarpa
%A Eileen P Treacy
%A Anna Tylki-Szymanska
%A J Edmond Wraith
%A Jiri Zeman
%A Frits A Wijburg
%J Orphanet Journal of Rare Diseases
%D 2012
%I BioMed Central
%R 10.1186/1750-1172-7-22
%X A consensus procedure based on a combined modified Delphi method and a nominal group technique was undertaken. It consisted of two written rounds and a face-to-face meeting. Sixteen MPS I experts participated in the process. The main goal was to identify the most important indicators of phenotypic severity and include these in a numerical severity scale. The correlation between the median subjective expert MPS I rating and the scores derived from this severity scale was used as an indicator of validity.Full consensus was reached on six key clinical items for assessing severity: age of onset of signs and symptoms, developmental delay, joint stiffness/arthropathy/contractures, kyphosis, cardiomyopathy and large head/frontal bossing. Due to the remarkably large variability in the expert MPS I assessments, however, a reliable numerical scale could not be constructed. Because of this variability, such a scale would always result in patients whose calculated severity score differed unacceptably from the median expert severity score, which was considered to be the 'gold standard'.Although consensus was reached on the six key items for assessing phenotypic severity in MPS I, expert opinion on phenotypic severity at diagnosis proved to be highly variable. This subjectivity emphasizes the need for validated biomarkers and improved genotype-phenotype correlations that can be incorporated into phenotypic severity assessments at diagnosis.Mucopolysaccharidosis type I (MPS I; OMIM #252800) is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the alpha-L-iduronidase (IDUA) enzyme, which is involved in the breakdown of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate [1]. The resulting GAG accumulation leads to cellular and organ dysfunction. More than 140 different mutations in the IDUA gene have been described [2,3]. The birth prevalence varies from 1 in 26,000 (in the Irish Republic) to less than 1 in 900,000 (in Taiwan) [4,5].MPS
%K Mucopolysaccharidosis type I
%K Iduronidase
%K Classification
%K Consensus
%K Phenotype
%K Hematopoietic stem cell transplantation
%U http://www.ojrd.com/content/7/1/22